Drug Trial Radar · NCT00148941
Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines
Last checked: Nov 20, 2026Latest source record: Feb 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,209
Actual
Start
Jan 6, 2005
Primary completion
Nov 1, 2006
Study completion Dec 4, 2006
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Sep 8, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 4 years, up to 6 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aims of this trial are to demonstrate the consistency of three manufacturing lots of GSK Biologicals' DTaP-IPV candidate vaccine in terms of immunogenicity and to evaluate the non-inferiority of GSK Biologicals' DTaP-IPV vaccine with respect to immunogenicity and safety compared to the control vaccines (separate injections of GSK Biologicals' DTaP vaccine \[Infanrix\] and Aventis Pasteur's IPV vaccine \[IPOL\]) when administered as a 5th dose of DTaP and a 4th dose of inactivated poliovirus vaccine in subjects 4 to 6 years of age. Vaccines will be co-administered with the second dose of M-M-RII, which is recommended at this age. Concomitant administration of a US-licensed influenza vaccine will be allowed according to seasonal availability of vaccine and at the discretion of the investigator.
Conditions
- Tetanus
- Acellular Pertussis
- Diphtheria
Interventions
SB213503 lot 1Biological
SB213503 lot 1 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
SB213503 lot 2Biological
SB213503 lot 2 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
SB213503 lot 3Biological
SB213503 lot 3 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
InfanrixBiological
Infanrix vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
IPOLBiological
IPOL vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.
M-M-R IIBiological
M-M-R II vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric Mean Concentrations (GMCs) for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies in a Subset of SubjectsTime frame: At Month 1 (i.e. one month after vaccination)
- Geometric Mean Concentrations (GMCs) for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibodies in a Subset of SubjectsTime frame: At Month 1 (i.e. one month after vaccination)
- Geometric Mean Titers (GMTs) for Anti-poliovirus Types 1, 2 and 3 Antibodies in a Subset of SubjectsTime frame: At Month 1 (i.e. one month after vaccination)
- Number of Subjects With Booster Response Against Diphtheria Toxoid (D) and Tetanus Toxoid (T) Antigens in a Subset of SubjectsTime frame: At Month 1 (i.e. one month after vaccination)
- Number of Subjects With Booster Response Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) Antigens in a Subset of SubjectsTime frame: At Month 1 (i.e. one month after vaccination)
- Number of Subjects With Circumferential Swelling at the Injection SiteTime frame: Within 4 days (Day 0-3) after vaccination
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Antioch, California
GSK Investigational Site
Daly City, California
GSK Investigational Site
Fairfield, California
GSK Investigational Site
Fremont, California
GSK Investigational Site
Fresno, California
GSK Investigational Site
Hayward, California
GSK Investigational Site
Oakland, California
GSK Investigational Site
Pleasanton, California
GSK Investigational Site
Redwood City, California
GSK Investigational Site
Richmond, California
GSK Investigational Site
Roseville, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
San Francisco, California
GSK Investigational Site
San Jose, California
GSK Investigational Site
San Ramon, California
GSK Investigational Site
Santa Clara, California
GSK Investigational Site
Santa Rosa, California
GSK Investigational Site
Vacaville, California
GSK Investigational Site
Vallejo, California
GSK Investigational Site
Walnut Creek, California
GSK Investigational Site
Columbus, Ohio
GSK Investigational Site
Mechanicsville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.